癌变·畸变·突变

• 论著 • 上一篇    下一篇

氧化苦参碱抗流感病毒药效及机制研究

陈小璇,代剑平*,万倩英,朱丹霞,王革非,李康生   

  1. 汕头大学医学院微生物与免疫学教研室,广东  汕头  515041
  • 收稿日期:2013-12-25 修回日期:2014-04-01 出版日期:2014-05-30 发布日期:2014-05-30
  • 通讯作者: 代剑平,E-mail:daijpedu2008@163.com
  • 作者简介:陈小璇(1984- ),女,广东省普宁市人,本科,助理实验师,研究方向:免疫药理学。E-mail:chen.x.x.85@163.com
  • 基金资助:

    国家自然科学基金项目(81374040)

The effects and mechanisms of oxymatrine on anti- influenza A virus activity

CHEN Xiao-xuan,DAI Jian-ping*,WAN Qian-ying,ZHU Dan-xia,WANG Ge-fei,LI Kang-sheng   

  1. Department of Microbiology and Immunology, Shantou University Medical College, Shantou 515041, Guangdong, China
  • Received:2013-12-25 Revised:2014-04-01 Online:2014-05-30 Published:2014-05-30

摘要:

目的: 研究氧化苦参碱的抗流感病毒活性及其潜在机制。方法:培养MDCK和A549细胞,并设空白对照组(DMSO, 0.5%)、病毒处理组、阳性对照组(利巴韦林,200 μmol/L)和氧化苦参碱处理组(12.5、25、50、100 μmol/L),每组重复6孔。空斑抑制法测定氧化苦参碱抗病毒药效;构建荧光素酶报告质粒,并用Western blot和ELISA检测氧化苦参碱对流感病毒诱导的细胞Toll样受体4(TLR4)、髓样分化因子88(MyD88)和肿瘤坏死因子受体相关因子6(TRAF6)启动子转录、TLR4-Myd88-TRAF6-NF-κB信号通路活化及炎性因子释放的影响。结果:空斑抑制实验显示氧化苦参碱在12.5~100 μmol/L范围内可显著降低流感病毒复制,其半数有效浓度(EC50)为19.95 μmol/L。与病毒处理组比较,启动子荧光素酶报告质粒检测显示12.5 μmol/L氧化苦参碱可显著降低流感病毒诱导的TLR4、MyD88和TRAF6转录(P<0.05);Western blot检测显示12.5 μmol/L氧化苦参碱可显著降低流感病毒诱导的TLR4-Myd88-TRAF6-NF-κB通路的活化(P<0.05);ELISA检测显示12.5 μmol/L氧化苦参碱可显著降低流感病毒诱导的IL-1β、IL-6、TNF-α、IL-8、IFN-β和IFN-γ释放(P<0.05)。结论:氧化苦参碱具抗流感病毒活性,其潜在机制可能与其抑制流感病毒诱导的TLR4-Myd88-TRAF6-NF-κB信号通路活化有关。

关键词: 氧化苦参碱, 流感病毒, TLR4信号通路, 炎性因子

Abstract:

OBJECTIVE: To explore the effects and mechanisms of oxymatrine on anti-influenza A virus (IAV) activity. METHODS: MDCK and A549 cells were cultured and divided into 4 groups: blank control (DMSO, 0.5%), virus-treated group,positive group (ribavirin,200 μmol/L) and oxymatrine-treated group (12.5,25,50 and 100 μmol/L) ,with 6 repeats in each group. The anti-IAV activity of oxymatrine was determined by plaque inhibition assay. The influence of oxymatrine on the IAV-induced transcription of TLR4,MyD88 and TRAF6,the activation of TLR4-Myd88-TRAF6-NF-κB signal pathway,and the release of inflammatory cytokins were determined by luciferase reporter plasmid,Western blot and ELISA assays,respectively. RESULTS: Plaque inhibition assay showed that oxymatrine, at a range of 12.5-100 μmol/L,could significantly inhibit the replication of IAV in vitro,and its EC50 was 19.95 μmol/L. Luciferase reporter assay showed that oxymatrine,at the concentration of 12.5 μmol/L,could significantly inhibit the transcription of TLR4,MyD88 and TRAF6 induced by IAV infection (compared with virus-treated group,P < 0.05). Western blot assay showed that oxymatrine (12.5 μmol/L) could significantly inhibit the IAV-induced activation of TLR4-Myd88-TRAF6-NF-κB pathway (compared with virus-treated group,P<0.05). ELISA assay showed that oxymatrine (12.5 μmol/L) could significantly inhibit the IAV-induced release of inflammatory cytokins (compared with virus-treated group,P< 0.05). CONCLUSION: Oxymatrine possessed anti-IAV activity,and its mechanism may be related to its ability to inhibit the IAV-induced activation of TLR4-MyD88-TRAF6-NF-κB pathway.

Key words: oxymatrine, influenza A virus, TLR4 pathway, inflammatory cytokines